- Home
- KROS vs BRSP Comparison
KROS vs BRSP Comparison
Compare KROS & BRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KROS
- BRSP
- Stock Information
- Founded
- KROS 2015
- BRSP 2017
- Country
- KROS United States
- BRSP United States
- Employees
- KROS N/A
- BRSP N/A
- Industry
- KROS Biotechnology: Pharmaceutical Preparations
- BRSP Real Estate Investment Trusts
- Sector
- KROS Health Care
- BRSP Real Estate
- Exchange
- KROS Nasdaq
- BRSP Nasdaq
- Market Cap
- KROS 565.0M
- BRSP 665.4M
- IPO Year
- KROS 2020
- BRSP 2018
- Fundamental
- Price
- KROS $14.51
- BRSP $4.97
- Analyst Decision
- KROS Buy
- BRSP Buy
- Analyst Count
- KROS 13
- BRSP 4
- Target Price
- KROS $20.63
- BRSP $6.38
- AVG Volume (30 Days)
- KROS 450.7K
- BRSP 700.0K
- Earning Date
- KROS 08-06-2025
- BRSP 07-29-2025
- Dividend Yield
- KROS N/A
- BRSP 12.85%
- EPS Growth
- KROS N/A
- BRSP N/A
- EPS
- KROS 0.11
- BRSP N/A
- Revenue
- KROS $214,713,000.00
- BRSP $340,600,000.00
- Revenue This Year
- KROS $5,390.70
- BRSP N/A
- Revenue Next Year
- KROS N/A
- BRSP $12.19
- P/E Ratio
- KROS $133.17
- BRSP N/A
- Revenue Growth
- KROS 91657.70
- BRSP N/A
- 52 Week Low
- KROS $9.12
- BRSP $4.16
- 52 Week High
- KROS $72.37
- BRSP $6.46
- Technical
- Relative Strength Index (RSI)
- KROS 58.66
- BRSP 44.67
- Support Level
- KROS $14.18
- BRSP $4.87
- Resistance Level
- KROS $14.85
- BRSP $5.05
- Average True Range (ATR)
- KROS 0.55
- BRSP 0.10
- MACD
- KROS 0.04
- BRSP -0.01
- Stochastic Oscillator
- KROS 71.78
- BRSP 38.46
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About BRSP BrightSpire Capital Inc.
BrightSpire Capital Inc is an internally-managed commercial real estate credit REIT focused on originating, acquiring, financing and managing a diversified portfolio of commercial real estate debt and net lease real estate investments predominantly in the United States. CRE debt investments consist of first mortgage loans with the objective of generating consistent risk-adjusted returns. The operating segments of the company are Senior and Mezzanine Loans and Preferred Equity, Net Leased and Other Real Estate, Corporate and Other. Geographically, the company generates revenue from the United States.